DonCorleone77 Posted - 3 weeks ago

$TYRA Tyra Biosciences 'rapidly becoming' top second half pick at Opco Oppenheimer reiterates an Outperform rating on Tyra Biosciences with a $28 price target, saying the company is "rapidly becoming" a top pick for the second half of 2024. "The fact that Tyra shares have been resilient despite the long wait for Phase 1 data tells us the story is resonating with investors," the analyst tells investors in a research note. Urothelial cancer and achondroplasia are each $2B-plus markets and TYRA-300 is "head-and-shoulders better than competitors," the firm contends. It believes Vosoritide's recent data showed that increasing height velocity can be done safety removes a common misperception to Tyra's approach.

DonCorleone77 Posted - 3 weeks ago

$TYRA Tyra Biosciences reports preclinical proof-of-concept results with TYRA-300 Tyra Biosciences announced preclinical proof-of-concept results with TYRA-300, an investigational oral FGFR3 selective inhibitor, in hypochondroplasia, or HCH. The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference, held June 28-30,in Baltimore. HCH is a skeletal dysplasia closely related to achondroplasia, or ACH, the most common form of dwarfism. HCH is most commonly caused by the N540K mutation in the FGFR3 gene. There are currently no approved therapeutic options for HCH. The design of TYRA-300 may inhibit the alteration driving FGFR3-related skeletal dysplasias including ACH, HCH and others. In an Fgfr3Asn534Lys/+ preclinical model, TYRA-300 was evaluated in FGFR3 wild-type and mutant animals to evaluate its potential effect on long bone length and skull size compared to vehicle-treated mice. TYRA-300 was administered daily at 1.8 mg/kg/day for 21 days starting at Day 3. TYRA-300 increased the length of the appendicular skeleton in the FGFR3 mutated mice: femur by 3.70% compared to the vehicle; tibia by 3.75% compared to the vehicle; humerus by 3.22% compared to the vehicle; and ulna by 5.03% compared to the vehicle. TYRA-300 also increased the size of the foramen magnum by 5.88% in mice. TYRA-300 demonstrated binding against the FGFR3 N540K altered protein and isoform selectivity for FGFR3 over other isoforms, as previously reported.

Stock_Titan Posted - 3 weeks ago

$TYRA Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH) https://www.stocktitan.net/news/TYRA/tyra-biosciences-announces-preclinical-proof-of-concept-results-with-o7ovg79q5b4b.html

Stocksrunner Posted - 1 month ago

$TYRA has been on a roll, with a recent 11.5% gain. With analysts forecasting further upside, it’s a stock to keep an eye on for potential breakout opportunities.

DonCorleone77 Posted - 2 months ago

$TYRA Tyra Biosciences price target raised to $28 from $25 at Oppenheimer Oppenheimer raised the firm's price target on Tyra Biosciences to $28 from $25 and keeps an Outperform rating on the shares following the company's Q1 earnings results. The firm noted that it has recently noticed an uptick in investor interest in the story, which it feels "isn't surprising as we approach initial data from SURF301 later this year."

Thestocktraderhubzee Posted - 2 months ago

$TYRA HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target

DonCorleone77 Posted - 2 months ago

$TYRA Tyra Biosciences reports Q1 EPS (35c), consensus (45c) "During the first quarter of 2024, we focused on execution across our pipeline including delivering on our near-term milestones for TYRA-300 in both achondroplasia and oncology," said Todd Harris, CEO of TYRA. "In oncology, the TYRA-300 clinical profile continues to mature in SURF301, and our clinical team is focused on Part B dose expansion to evaluate multiple dosing regimens of TYRA-300. We believe this work will support future Phase 2 studies in NMIBC and metastatic urothelial carcinoma, where we see tremendous opportunity for an oral FGFR3-selective inhibitor. In achondroplasia, we remain on track to submit our IND in the second half of 2024 to support our planned Phase 2 study."

Stock_Titan Posted - 2 months ago

$TYRA Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-first-quarter-2024-financial-results-and-0urr5hljmef3.html

Doozio Posted - 2 months ago

$TYRA wen 🧠⏰ if no faatch 💣?

DailyStocksPicks Posted - 4 months ago

Acelyrin ($SLRN): Acelyrin’s stock is perceived as oversold due to the divergence between its clinical advancements, institutional support, and analysts' optimistic forecasts versus its recent stock performance. Despite facing downward pressure, the company’s engagement in critical clinical trials and backing from notable institutional investors suggest an underappreciation of its value and potential, especially when considering its innovative pipeline in addressing unmet medical needs. $TYRA, $ZYME, $PHVS, $WVE For More Details: https://youtu.be/yeL_bMBSsNQ

erevnon Posted - 4 months ago

Wedbush reiterates Tyra Biosciences $TYRA at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

fda_tracker Posted - 4 months ago

$TYRA New PDUFA Date 2024-04-23 Tyra Biosciences, Inc. Link:https://www.sec.gov/Archives/edgar/data/0001863127/000095017024033461/tyra-20231231.htm Calendar:http://www.fdatracker.com/fda-calendar/

erevnon Posted - 4 months ago

HC Wainwright & Co. reiterates Tyra Biosciences $TYRA at Buy and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/

DonCorleone77 Posted - 4 months ago

$TYRA Tyra Biosciences files to sell 15.37M shares of common stock for holders

DonCorleone77 Posted - 4 months ago

$TYRA Tyra Biosciences reports Q4 EPS (53c), consensus (48c) As of December 31, 2023, TYRA had cash, cash equivalents, and marketable securities of $203.5M. "2023 was an outstanding year for TYRA and we are pleased to have positive momentum at the start of 2024," said Todd Harris, CEO of TYRA. "We have strong conviction in our pipeline and believe our lead program TYRA-300 has the potential to become a best-in-class agent for multiple high-value indications. TYRA-300 remains our top priority and we are focused on submitting our Phase 2 IND for achondroplasia, while optimizing dose in SURF301 in preparation for Phase 2 studies in NMIBC and metastatic urothelial carcinoma."

Stock_Titan Posted - 4 months ago

$TYRA Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2023-financial-3736evb31ve4.html

insiderbuyingselling Posted - 4 months ago

$TYRA new insider selling: 200 shares. http://insiderbuyingselling.com/?t=TYRA

Stock_Titan Posted - 02/27/24

$TYRA Tyra Biosciences to Present at Upcoming Investor Conferences https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-present-at-upcoming-investor-ymxalybdlpqb.html

insiderbuyingselling Posted - 5 months ago

$TYRA new insider selling: 1501 shares. http://insiderbuyingselling.com/?t=TYRA

StockScanners Posted - 5 months ago

$TYRA We reached 20 lets go!, testing resistance, lets see what this does into next week

insiderbuyingselling Posted - 5 months ago

$TYRA new insider selling: 9587 shares. http://insiderbuyingselling.com/?t=TYRA

ArcherGreenaway Posted - 5 months ago

$EVER $TYRA $SSP Analyst price target for today() https://live-alerts-stock-trades.daytrading.network

Stock_Titan Posted - 5 months ago

$TYRA Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-present-at-oppenheimer-s-34th-annual-healthcare-9ea44vd4hkyv.html

TickerDD_com Posted - 5 months ago

From 12/22/2023, looking back across 22 Month-Ends for TYRA, Percentage Change of Average Monthly Price had More Positives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $TYRA #TYRA #TYRAStock #TickerDD #TYRAPrice https://www.youtube.com/watch?v=RYkrz2UwRRQ

RealisticPerson Posted - 5 months ago

$NYCB diff sector but this one is up big on pp @ $13 and ceo selling ~ pipeline is only at phase 1... potential short/put plays. Not sure how its holding up so well but check out $TYRA

RealisticPerson Posted - 5 months ago

$TYRA wow so much confidence here....

Noisy Posted - 5 months ago

$TYRA very resilient, ceo sells 100000 shares and the stock still goes up lol

insiderbuyingselling Posted - 5 months ago

$TYRA new insider selling: 100000 shares. http://insiderbuyingselling.com/?t=TYRA

Doozio Posted - 5 months ago

$TYRA chop chop huckleberries 🧠⏰

StockScanners Posted - 5 months ago

$TYRA Reached 18.48, keep on watch